Pharsight

1. Drug name - ABILIFY MYCITE KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10517507	OTSUKA	Communication system with enhanced partial power source and method of manufacturing same	Jun, 2032 (9 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

2. Drug name - ABRAXANE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393318	ABRAXIS BIOSCIENCE	Methods of treating cancer	Mar, 2032 (9 years from now)
US9597409	ABRAXIS BIOSCIENCE	Methods of treating cancer	Mar, 2032 (9 years from now)
US9393318 (Pediatric)	ABRAXIS BIOSCIENCE	Methods of treating cancer	Sep, 2032 (9 years from now)
US9597409 (Pediatric)	ABRAXIS BIOSCIENCE	Methods of treating cancer	Sep, 2032 (9 years from now)

Drugs and Companies using PACLITAXEL ingredient

Treatment: Treatment of lung cancer

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription

3. Drug name - ACETADOTE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722738	CUMBERLAND PHARMS	Acetycysteine compositions and methods of use thereof	Apr, 2032 (9 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE;INTRAVENOUS

Strength	Dosage	Availability
6GM/30ML (200MG/ML)	INJECTABLE;INTRAVENOUS	Prescription

4. Drug name - ADZENYS ER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8709491	NEOS THERAPS INC	Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles	Jun, 2032 (9 years from now)
US9017731	NEOS THERAPS INC	Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles	Jun, 2032 (9 years from now)
US9265737	NEOS THERAPS INC	Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles	Jun, 2032 (9 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 1.25MG BASE/ML	SUSPENSION, EXTENDED RELEASE;ORAL	Discontinued

5. Drug name - ADZENYS XR-ODT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9017731	NEOS THERAPS	Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles	Jun, 2032 (9 years from now)
US9265737	NEOS THERAPS	Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles	Jun, 2032 (9 years from now)
US8709491	NEOS THERAPS	Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles	Jun, 2032 (9 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 3.1MG BASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
EQ 6.3MG BASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
EQ 9.4MG BASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
EQ 12.5MG BASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
EQ 15.7MG BASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
EQ 18.8MG BASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription

6. Drug name - AIRDUO DIGIHALER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (9 years from now)
US8978966	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jan, 2032 (9 years from now)
US8714149	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Feb, 2032 (9 years from now)
US10561808 (Pediatric)	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jul, 2032 (9 years from now)
US8978966 (Pediatric)	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jul, 2032 (9 years from now)
US8714149 (Pediatric)	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Aug, 2032 (9 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

7. Drug name - AKYNZEO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8426450	HELSINN HLTHCARE	Substituted 4-phenyl pyridines having anti-emetic effect	May, 2032 (9 years from now)
US9908907	HELSINN HLTHCARE	Substituted piperaziniums for the treatment of emesis	May, 2032 (9 years from now)
US9403772	HELSINN HLTHCARE	4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator	May, 2032 (9 years from now)
US10717721	HELSINN HLTHCARE	Substituted piperaziniums for the treatment of emesis	May, 2032 (9 years from now)
CN106986822B	HELSINN HLTHCARE	Substituted 4-Phenylpyridine For The Treatment Of Nk-1 Receptor Related Diseases	Nov, 2032 (10 years from now)
CN106518924B	HELSINN HLTHCARE	4 For Treating Substituted-Phenyl Pyridine Nk-1 Receptor Associated Diseases	Nov, 2032 (10 years from now)
CN106518924A	HELSINN HLTHCARE	For Treatment Of Substituted 4-Phenyl Pyridinium Nk-1 Receptor Associated Diseases	Nov, 2032 (10 years from now)
CN106986822A	HELSINN HLTHCARE	For Treatment Of Substituted 4-Phenyl Pyridinium Nk-1 Receptor Associated Diseases	Nov, 2032 (10 years from now)
IN201404907P4	HELSINN HLTHCARE	Substituted-4- Phenyl Pyridines For The Treatment Of Nk 1 Receptor Related Diseases	Nov, 2032 (10 years from now)
IN324179B	HELSINN HLTHCARE	Substituted 4-Phenyl-Pyridines For The Treatment Of Nk-1 Receptor Related Diseases	Nov, 2032 (10 years from now)
EP2785706A1	HELSINN HLTHCARE	Substituted 4-Phenyl-Pyridines For The Treatment Of Nk-1 Receptor Related Diseases.	Nov, 2032 (10 years from now)
EP2785706B1	HELSINN HLTHCARE	Substituted 4-Phenyl-Pyridines For The Treatment Of Nk-1 Receptor Related Diseases.	Nov, 2032 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10208073	HELSINN HLTHCARE	Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator	May, 2032 (9 years from now)
US8895586	HELSINN HLTHCARE	Methods of treating emesis	May, 2032 (9 years from now)

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription
EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

8. Drug name - ALECENSA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9365514	HOFFMANN-LA ROCHE	Composition comprising tetracyclic compound	Mar, 2032 (9 years from now)

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 150MG BASE	CAPSULE;ORAL	Prescription

9. Drug name - ALIQOPA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10383876	BAYER HEALTHCARE	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts	Mar, 2032 (9 years from now)
CN103649091A	BAYER HEALTHCARE	Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts	Mar, 2032 (9 years from now)
CN103649091B	BAYER HEALTHCARE	Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts	Mar, 2032 (9 years from now)
EP2694508A1	BAYER HEALTHCARE	Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts	Mar, 2032 (9 years from now)
EP2694508B1	BAYER HEALTHCARE	Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts	Mar, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344	BAYER HEALTHCARE	Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts	Mar, 2032 (9 years from now)

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
60MG/VIAL	POWDER;INTRAVENOUS	Prescription

10. Drug name - ALKINDI SPRINKLE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717740	ETON	Treatment of adrenal insufficiency	Nov, 2032 (10 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
0.5MG	GRANULE;ORAL	Prescription
1MG	GRANULE;ORAL	Prescription
2MG	GRANULE;ORAL	Prescription
5MG	GRANULE;ORAL	Prescription

11. Drug name - APTIOM

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750747	SUNOVION PHARMS INC	Treatments involving eslicarbazepine acetate or eslicarbazepine	Aug, 2032 (9 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; treatment of partial-onset seizures

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG	TABLET;ORAL	Prescription
400MG	TABLET;ORAL	Prescription
600MG	TABLET;ORAL	Prescription
800MG	TABLET;ORAL	Prescription

12. Drug name - ARISTADA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226458	ALKERMES INC	Pharmaceutical compositions comprising sorbitan esters	Mar, 2032 (9 years from now)
US9034867	ALKERMES INC	Pharmaceutical compositions comprising sorbitan esters	Nov, 2032 (10 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
441MG/1.6ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
662MG/2.4ML (275.83MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
882MG/3.2ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
1064MG/3.9ML (272.82MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

13. Drug name - ARMONAIR DIGIHALER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (9 years from now)
US8978966	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jan, 2032 (9 years from now)
US8714149	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Feb, 2032 (9 years from now)
US10561808 (Pediatric)	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jul, 2032 (9 years from now)
US8978966 (Pediatric)	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jul, 2032 (9 years from now)
US8714149 (Pediatric)	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Aug, 2032 (9 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH	POWDER;INHALATION	Discontinued
0.113MG/INH	POWDER;INHALATION	Discontinued
0.232MG/INH	POWDER;INHALATION	Discontinued
0.03MG/INH	POWDER;INHALATION	Discontinued

14. Drug name - AVYCAZ

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8969566	ALLERGAN	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof	Jun, 2032 (9 years from now)
US9695122	ALLERGAN	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof	Jun, 2032 (9 years from now)
US9284314	ALLERGAN	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof	Jun, 2032 (9 years from now)
CN105294690A	ALLERGAN	The Preparation Comprises -7 - Oxo -6-(Sulfo-Oxy) -1, 6-Diazabicyclo [3 2 1] Octane - -2 - Formamide Heterocyclic Compound And Salt Thereof	Jun, 2032 (9 years from now)
CN103649051A	ALLERGAN	Method For Preparing Heterocyclic Compound Comprising Reverse-7-Oxo- -6-(Sulfo Group) -1, 6-Two [3, 2, 1] -2 -Carboxamide And The Salt Thereof	Jun, 2032 (9 years from now)
CN103649051B	ALLERGAN	Method For Preparing Heterocyclic Compound Comprising Reverse-7-Oxo- -6-(Sulfo Group) -1, 6-Two [3, 2, 1] -2 -Carboxamide And The Salt Thereof	Jun, 2032 (9 years from now)
CN105294690B	ALLERGAN	Preparation Comprising Anti - -7 - Oxo - -6-(Sulfo Group) -1, 6-Di-Aza-Bicyclo (3, 2, 1] -2 - Formamide Heterocyclic Compound And Its Salt Method	Jun, 2032 (9 years from now)
EP2721005B1	ALLERGAN	Process For Preparing Heterocyclic Compounds Including Trans-7-Oxo-6-(Sulphooxy)-1,6-Diazabicyclo[3,2,1]Octane-2-Carboxamide And Salts Thereof	Jun, 2032 (9 years from now)
EP2721005A1	ALLERGAN	Process For Preparing Heterocyclic Compounds Including Trans-7-Oxo-6-(Sulphooxy)-1,6-Diazabicyclo[3,2,1]Octane-2-Carboxamide And Salts Thereof	Jun, 2032 (9 years from now)

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 0.5GM BASE;2GM/VIAL	POWDER;INTRAVENOUS	Prescription

15. Drug name - AZSTARYS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928	COMMAVE THERAP	Methylphenidate-oxoacid conjugates, processes of making and using the same	Jul, 2032 (9 years from now)

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 5.2MG BASE;EQ 26.1MG BASE	CAPSULE;ORAL	Prescription
EQ 7.8MG BASE;EQ 39.2MG BASE	CAPSULE;ORAL	Prescription
EQ 10.4MG BASE;EQ 52.3MG BASE	CAPSULE;ORAL	Prescription

16. Drug name - BELBUCA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901539	BDSI	Transmucosal drug delivery devices for use in chronic pain relief	Dec, 2032 (10 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: FILM;BUCCAL

Strength	Dosage	Availability
EQ 0.075MG BASE	FILM;BUCCAL	Prescription
EQ 0.15MG BASE	FILM;BUCCAL	Prescription
EQ 0.3MG BASE	FILM;BUCCAL	Prescription
EQ 0.45MG BASE	FILM;BUCCAL	Prescription
EQ 0.6MG BASE	FILM;BUCCAL	Prescription
EQ 0.75MG BASE	FILM;BUCCAL	Prescription
EQ 0.9MG BASE	FILM;BUCCAL	Prescription

17. Drug name - BIJUVA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10639375	THERAPEUTICSMD INC	Progesterone formulations	Nov, 2032 (10 years from now)
US10206932	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US8846649	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US8846648	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US9114146	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US9114145	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US10675288	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US9301920	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US11033626	THERAPEUTICSMD INC	Progesterone formulations having a desirable pk profile	Nov, 2032 (10 years from now)
US9006222	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US10806740	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US11103513	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US8933059	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US8633178	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US8987237	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US8993549	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US11103516	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US11166963	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US10052386	THERAPEUTICSMD INC	Progesterone formulations	Nov, 2032 (10 years from now)
US8993548	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)
US11110099	THERAPEUTICSMD INC	Natural combination hormone replacement formulations and therapies	Nov, 2032 (10 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Treatment: Treatment of menopause symptoms, including vasomotor symptoms

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
0.5MG;100MG	CAPSULE;ORAL	Prescription
1MG;100MG	CAPSULE;ORAL	Prescription

18. Drug name - BIKTARVY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9296769	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
US8754065	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
EP2744810B1	GILEAD SCIENCES INC	Tenofovir Alafenamide Hemifumarate	Aug, 2032 (9 years from now)
EP2744810A1	GILEAD SCIENCES INC	Tenofovir Alafenamide Hemifumarate	Aug, 2032 (9 years from now)

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 30MG BASE;120MG;EQ 15MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE;200MG;EQ 25MG BASE	TABLET;ORAL	Prescription

19. Drug name - BORTEZOMIB

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962572	FRESENIUS KABI USA	Bortezomib formulations	Nov, 2032 (10 years from now)

Drugs and Companies using BORTEZOMIB ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
3.5MG/VIAL	POWDER;INTRAVENOUS	Prescription

20. Drug name - BRAFTOVI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9763941	ARRAY BIOPHARMA INC	Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate	Nov, 2032 (10 years from now)
US10258622	ARRAY BIOPHARMA INC	Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate	Nov, 2032 (10 years from now)
US9387208	ARRAY BIOPHARMA INC	Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate	Nov, 2032 (10 years from now)

Drugs and Companies using ENCORAFENIB ingredient

Treatment: Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
50MG	CAPSULE;ORAL	Discontinued
75MG	CAPSULE;ORAL	Prescription

21. Drug name - BUNAVAIL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703177	BDSI	Abuse-resistant mucoadhesive devices for delivery of buprenorphine	Aug, 2032 (9 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: FILM;BUCCAL

Strength	Dosage	Availability
EQ 2.1MG BASE;EQ 0.3MG BASE	FILM;BUCCAL	Discontinued
EQ 4.2MG BASE;EQ 0.7MG BASE	FILM;BUCCAL	Discontinued
EQ 6.3MG BASE;EQ 1MG BASE	FILM;BUCCAL	Discontinued

22. Drug name - CALDOLOR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072710	CUMBERLAND PHARMS	Injectable ibuprofen formulation	Mar, 2032 (9 years from now)
US9072661	CUMBERLAND PHARMS	Injectable ibuprofen formulation	Mar, 2032 (9 years from now)

Drugs and Companies using IBUPROFEN ingredient

Treatment: Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
400MG/4ML (100MG/ML)	SOLUTION;INTRAVENOUS	Discontinued
800MG/8ML (100MG/ML)	SOLUTION;INTRAVENOUS	Prescription
800MG/200ML (4MG/ML)	SOLUTION;INTRAVENOUS	Prescription

23. Drug name - CALQUENCE

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9290504	ASTRAZENECA	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors	Jul, 2032 (9 years from now)
CN103889987A	ASTRAZENECA	As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide	Jul, 2032 (9 years from now)
CN106243113A	ASTRAZENECA	Imidazole As Selective Btk Inhibitors And Paradiazine	Jul, 2032 (9 years from now)
CN103889987B	ASTRAZENECA	Imidazole As Selective Btk Inhibitors And Paradiazine	Jul, 2032 (9 years from now)
CN106243113B	ASTRAZENECA	As A Selective Btk Inhibitor And Pyrazine	Jul, 2032 (9 years from now)
EP3689878B1	ASTRAZENECA	4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors	Jul, 2032 (9 years from now)
EP3689878A1	ASTRAZENECA	4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors	Jul, 2032 (9 years from now)
EP2734522B1	ASTRAZENECA	4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors	Jul, 2032 (9 years from now)
EP2734522A1	ASTRAZENECA	4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors	Jul, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883	ASTRAZENECA	4-imidazopyridazin-1-yl-benzamides as BTK inhibitors	Jul, 2032 (9 years from now)
US9758524	ASTRAZENECA	4-imidazopyridazin-1-yl-benzamides as Btk inhibitors	Jul, 2032 (9 years from now)

Drugs and Companies using ACALABRUTINIB ingredient

Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
100MG	CAPSULE;ORAL	Prescription

24. Drug name - CASPOFUNGIN ACETATE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636407	FRESENIUS KABI USA	Caspofungin acetate formulations	Dec, 2032 (10 years from now)

Drugs and Companies using CASPOFUNGIN ACETATE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
50MG/VIAL	POWDER;INTRAVENOUS	Prescription
70MG/VIAL	POWDER;INTRAVENOUS	Prescription

25. Drug name - CETYLEV

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427421	ARBOR PHARMS LLC	Effervescent compositions containing N-acetylcysteine	May, 2032 (9 years from now)
US9561204	ARBOR PHARMS LLC	Effervescent compositions containing N-acetylcysteine	May, 2032 (9 years from now)
US8747894	ARBOR PHARMS LLC	Effervescent compositions containing N-acetylcysteine	May, 2032 (9 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: TABLET, EFFERVESCENT;ORAL

Strength	Dosage	Availability
2.5GM	TABLET, EFFERVESCENT;ORAL	Discontinued
500MG	TABLET, EFFERVESCENT;ORAL	Discontinued

26. Drug name - COMETRIQ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717720	EXELIXIS	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds	Feb, 2032 (9 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	CAPSULE;ORAL	Prescription
EQ 80MG BASE	CAPSULE;ORAL	Prescription

27. Drug name - CONTRAVE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248123	NALPROPION	Methods of providing weight loss therapy in patients with major depression	Jan, 2032 (9 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
90MG;8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

28. Drug name - COPIKTRA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46621	SECURA	Processes for preparing isoquinolinones and solid forms of isoquinolinones	May, 2032 (9 years from now)
CN103648499B	SECURA	Preparation Method For Isoquinoline Ketone And Solid Form Of Isoquinoline Ketone	Jan, 2032 (9 years from now)
CN103648499A	SECURA	Preparation Method For Isoquinoline Ketone And Solid Form Of Isoquinoline Ketone	Jan, 2032 (9 years from now)
EP3238722B1	SECURA	Solid Forms Of Isoquinolinones	Jan, 2032 (9 years from now)
EP2663309A1	SECURA	Processes For Preparing Isoquinolinones And Solid Forms Of Isoquinolinones	Jan, 2032 (9 years from now)
EP2663309B1	SECURA	Processes For Preparing Isoquinolinones And Solid Forms Of Isoquinolinones	Jan, 2032 (9 years from now)
EP3238722A1	SECURA	Solid Forms Of Isoquinolinones	Jan, 2032 (9 years from now)
EP2663309A4	SECURA	Processes For Preparing Isoquinolinones And Solid Forms Of Isoquinolinones	Jan, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9840505	SECURA	Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof	Jan, 2032 (9 years from now)

Drugs and Companies using DUVELISIB ingredient

Treatment: For the treatment of patients with follicular lymphoma (fl); for the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
15MG	CAPSULE;ORAL	Prescription
25MG	CAPSULE;ORAL	Prescription

29. Drug name - COTEMPLA XR-ODT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089496	NEOS THERAPS INC	Compositions comprising methylphenidate complexed with ion-exchange resin particles	Jun, 2032 (9 years from now)
US9072680	NEOS THERAPS INC	Compositions comprising methylphenidate complexed with ion-exchange resin particles	Jun, 2032 (9 years from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
8.6MG	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
17.3MG	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription
25.9MG	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	Prescription

30. Drug name - CYCLOSET

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688094	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US8613947	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US11000522	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US9700555	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US9993474	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US9192576	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US9522117	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)
US8431155	VEROSCIENCE	Bromocriptine formulations	Apr, 2032 (9 years from now)

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 2 and 3; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 4 and 5; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 7, 8, and 9; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 2; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 4, 5, and 6; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 7 and 8; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 10 and 11; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 16, 17, and 18; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 13 and 14; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 10, 11, and 12; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 16 and 17; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 13, 14, and 15; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 28 and 29; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 25 and 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 22, 23, and 24; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 19 and 20; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 19, 20, and 21; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 28, 29, and 30; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 25, 26, and 27; Improvement of glycemic control in individuals with type 2 diabetes; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 11; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13 and 23; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1, 11, and 12; adjunct to diet exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13, 23, and 24; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 41, 52, and 53; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 66, 75, and 76; adjunct to diet and execrise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 29, 39, and 40; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1, 13, and 14; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 54 and 64; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 29 and 39; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 13; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 66 and 75; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 41 and 52; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 89, 99, and 100; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 54, 64, and 65; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 15, 27, and 28; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 15 and 27; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 77 and 87; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 89 and 99; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 77, 87, and 88; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 43, 50 and 51; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 1,10 and 11; adjunct to diet and excercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 30, 41, and 42; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 1 and 10; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 30 and 41; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21 and 28; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 12 and 19; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 43 and 50; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 12, 19 and 20; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21, 28, and 29; Administration once daily within two hours after waking in the morning for improvement of glycemic control in a type 2 diabetes patient; improvement of glycemic control in individuals with type 2 diabetes

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.8MG BASE	TABLET;ORAL	Prescription

31. Drug name - DEFITELIO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11236328	JAZZ PHARMS INC	Euglobulin-based method for determining the biological activity of defibrotide	Jun, 2032 (9 years from now)
US11085043	JAZZ PHARMS INC	Euglobulin-based method for determining the biological activity of defibrotide	Jun, 2032 (9 years from now)

Drugs and Companies using DEFIBROTIDE SODIUM ingredient

Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (hsct)

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
200MG/2.5ML (80MG/ML)	SOLUTION;INTRAVENOUS	Prescription

32. Drug name - DESCOVY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9296769	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
US8754065	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
EP2744810B1	GILEAD SCIENCES INC	Tenofovir Alafenamide Hemifumarate	Aug, 2032 (9 years from now)
EP2744810A1	GILEAD SCIENCES INC	Tenofovir Alafenamide Hemifumarate	Aug, 2032 (9 years from now)

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
120MG;EQ 15MG BASE	TABLET;ORAL	Prescription
200MG;EQ 25MG BASE	TABLET;ORAL	Prescription

33. Drug name - DETECTNET

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10383961	RADIOMEDIX	PET tracer for imaging of neuroendocrine tumors	Aug, 2032 (9 years from now)
US11160888	RADIOMEDIX	PET tracer for imaging of neuroendocrine tumors	Aug, 2032 (9 years from now)
US10159759	RADIOMEDIX	Pet tracer for imaging of neuroendocrine tumors	Aug, 2032 (9 years from now)

Drugs and Companies using COPPER DOTATATE CU-64 ingredient

Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
4mL (1mCi/ML)	SOLUTION;INTRAVENOUS	Prescription

34. Drug name - DEXILANT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233103	TAKEDA PHARMS USA	Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy	Mar, 2032 (9 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
30MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription
60MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

35. Drug name - DEXYCU KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799642	EYEPOINT PHARMS	Dose guides for injection syringe	May, 2032 (9 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Treatment: NA

Dosage: SUSPENSION;INTRAOCULAR

Strength	Dosage	Availability
9%	SUSPENSION;INTRAOCULAR	Prescription

36. Drug name - DILAUDID

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731082	FRESENIUS KABI USA	Drug container	Apr, 2032 (9 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
0.2MG/ML	INJECTABLE;INJECTION	Prescription
1MG/ML	INJECTABLE;INJECTION	Prescription
2MG/ML	INJECTABLE;INJECTION	Prescription
4MG/ML	INJECTABLE;INJECTION	Discontinued
10MG/ML	INJECTABLE;INJECTION	Discontinued
250MG/VIAL	INJECTABLE;INJECTION	Discontinued

37. Drug name - DUZALLO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546436	IRONWOOD PHARMS INC	Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof	Feb, 2032 (9 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG;200MG	TABLET;ORAL	Discontinued
300MG;200MG	TABLET;ORAL	Discontinued

38. Drug name - EPANED KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8568747	SILVERGATE PHARMS	Enalapril compositions	Nov, 2032 (10 years from now)
US8778366	SILVERGATE PHARMS	Enalapril compositions	Nov, 2032 (10 years from now)
US9968553	SILVERGATE PHARMS	Enalapril compositions	Nov, 2032 (10 years from now)
US9855214	SILVERGATE PHARMS	Enalapril compositions	Nov, 2032 (10 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Treatment: Treatment of hypertension; method of treatment of heart failure; method of treating hypertension; treatment of heart failure; method of treating left ventricular dysfunction; Method of treatment of heart failure; treatment of hypertension; method of treating left ventricular dysfunction; method of treating hypertension; treatment of heart failure

Dosage: FOR SOLUTION;ORAL

Strength	Dosage	Availability
1MG/ML	FOR SOLUTION;ORAL	Discontinued

39. Drug name - EPCLUSA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8940718	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2032 (10 years from now)
US8921341	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2032 (10 years from now)
US8575135	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2032 (10 years from now)
CN103328480A	GILEAD SCIENCES INC	A Imidazole Imidazole For Condensation Of Antiviral Composition	Nov, 2032 (10 years from now)
CN105837584A	GILEAD SCIENCES INC	Condensed Imidazolyl-Imidazole As Antiviral Compound	Nov, 2032 (10 years from now)
CN105837584B	GILEAD SCIENCES INC	Condensation Of Imidazole Imidazole As Antivirus Compound	Nov, 2032 (10 years from now)
CN103328480B	GILEAD SCIENCES INC	Condensed Imidazolyl-Imidazole As Antiviral Compound	Nov, 2032 (10 years from now)
EP2907816A1	GILEAD SCIENCES INC	Condensed Imidazolylimidazoles As Antiviral Compounds	Nov, 2032 (10 years from now)
EP2635588A1	GILEAD SCIENCES INC	Condensed Imidazolylimidazoles As Antiviral Compounds	Nov, 2032 (10 years from now)
EP3431477B1	GILEAD SCIENCES INC	Condensed Imidazolylimidazoles As Antiviral Compounds	Nov, 2032 (10 years from now)
EP2907816B1	GILEAD SCIENCES INC	Condensed Imidazolylimidazoles As Antiviral Compounds	Nov, 2032 (10 years from now)
EP3431477A1	GILEAD SCIENCES INC	Condensed Imidazolylimidazoles As Antiviral Compounds	Nov, 2032 (10 years from now)
EP2635588B1	GILEAD SCIENCES INC	Condensed Imidazolylimidazoles As Antiviral Compounds	Nov, 2032 (10 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Treatment: NA

Dosage: PELLETS;ORAL

Strength	Dosage	Availability
150MG;37.5MG/PACKET	PELLETS;ORAL	Prescription
200MG;50MG/PACKET	PELLETS;ORAL	Prescription

40. Drug name - EVOTAZ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718	BRISTOL-MYERS SQUIBB	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (10 years from now)

Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 300MG BASE;150MG	TABLET;ORAL	Prescription

41. Drug name - EVZIO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8627816	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2032 (9 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
0.4MG/0.4ML (0.4MG/0.4ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

42. Drug name - EVZIO (AUTOINJECTOR)

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8627816	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2032 (9 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
2MG/0.4ML (2MG/0.4ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

43. Drug name - FETZIMA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8865937	ALLERGAN	Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide	May, 2032 (9 years from now)

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 40MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 80MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 120MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

44. Drug name - FIRDAPSE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11060128	CATALYST PHARMS	Methods of administering 3,4-diaminopyridine	Jun, 2032 (9 years from now)

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 10MG BASE	TABLET;ORAL	Prescription

45. Drug name - FIRMAGON

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415085	FERRING	Method of treating prostate cancer with GnRH antagonist	Apr, 2032 (9 years from now)
US10695398	FERRING	Method of treating prostate cancer with GnRH antagonist	Apr, 2032 (9 years from now)

Drugs and Companies using DEGARELIX ACETATE ingredient

Treatment: Method of treating prostate cancer

Dosage: POWDER;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 80MG BASE/VIAL	POWDER;SUBCUTANEOUS	Prescription
EQ 120MG BASE/VIAL	POWDER;SUBCUTANEOUS	Prescription

46. Drug name - GENVOYA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
US9296769	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
EP2744810B1	GILEAD SCIENCES INC	Tenofovir Alafenamide Hemifumarate	Aug, 2032 (9 years from now)
EP2744810A1	GILEAD SCIENCES INC	Tenofovir Alafenamide Hemifumarate	Aug, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718	GILEAD SCIENCES INC	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (10 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;150MG;200MG;EQ 10MG BASE	TABLET;ORAL	Prescription

47. Drug name - GILENYA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592208	NOVARTIS	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol	Mar, 2032 (9 years from now)
US9592208 (Pediatric)	NOVARTIS	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol	Sep, 2032 (9 years from now)

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

Treatment: Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 0.25MG BASE	CAPSULE;ORAL	Prescription
EQ 0.5MG BASE	CAPSULE;ORAL	Prescription

48. Drug name - GONITRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101592	POHL BOSKAMP	Stabilized granules containing glyceryl trinitrate	Mar, 2032 (9 years from now)

Drugs and Companies using NITROGLYCERIN ingredient

Treatment: NA

Dosage: POWDER;SUBLINGUAL

Strength	Dosage	Availability
0.4MG/PACKET	POWDER;SUBLINGUAL	Discontinued

49. Drug name - HARVONI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456414	GILEAD SCIENCES INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US9393256	GILEAD SCIENCES INC	Methods for treating HCV	Sep, 2032 (9 years from now)

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

Strength	Dosage	Availability
33.75MG;150MG/PACKET	PELLETS;ORAL	Prescription
45MG;200MG/PACKET	PELLETS;ORAL	Prescription

50. Drug name - ILEVRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921337	NOVARTIS	Carboxyvinyl polymer-containing nanoparticle suspensions	Mar, 2032 (9 years from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.3%	SUSPENSION/DROPS;OPHTHALMIC	Prescription

51. Drug name - IMVEXXY

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835487	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (10 years from now)
US9289382	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (10 years from now)
US10806697	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (10 years from now)
US11241445	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (10 years from now)
US11246875	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (10 years from now)
US10537581	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (10 years from now)

Drugs and Companies using ESTRADIOL ingredient

Treatment: Treatment of dyspareunia; treatment of a symptom of vulvar and vaginal atrophy

Dosage: INSERT;VAGINAL

Strength	Dosage	Availability
0.004MG	INSERT;VAGINAL	Prescription
0.01MG	INSERT;VAGINAL	Prescription

52. Drug name - INBRIJA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545878	ACORDA	Capsules containing high doses of levodopa for pulmonary use	Nov, 2032 (10 years from now)
US8685442	ACORDA	Capsules containing high doses of levodopa for pulmonary use	Nov, 2032 (10 years from now)
US9393210	ACORDA	Capsules containing high doses of levodopa for pulmonary use	Nov, 2032 (10 years from now)
US8945612	ACORDA	Capsules containing high doses of levodopa for pulmonary use	Nov, 2032 (10 years from now)

Drugs and Companies using LEVODOPA ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
42MG	POWDER;INHALATION	Prescription

53. Drug name - INREBIC

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10391094	IMPACT	Compositions and methods for treating myelofibrosis	Jun, 2032 (9 years from now)

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	CAPSULE;ORAL	Prescription

54. Drug name - IONSYS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8781571	THE MEDICINES CO	Switch validation circuit and method	Mar, 2032 (9 years from now)
US8428708	THE MEDICINES CO	Self-test for analgesic product	May, 2032 (9 years from now)
US8428709	THE MEDICINES CO	Current control for electrotransport drug delivery	Jun, 2032 (9 years from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

Strength	Dosage	Availability
EQ 40MCG BASE/ACTIVATION	SYSTEM;IONTOPHORESIS, TRANSDERMAL	Discontinued

55. Drug name - ISENTRESS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10772888	MERCK SHARP DOHME	Solid pharmaceutical compositions containing an integrase inhibitor	Mar, 2032 (9 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Treatment: Treatment of hiv-1 infection

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 400MG BASE	TABLET;ORAL	Prescription
EQ 600MG BASE	TABLET;ORAL	Prescription

56. Drug name - JORNAY PM

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10292937	IRONSHORE PHARMS	Methods of treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US10617651	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US10881618	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US11241391	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US11241392	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US9498447	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US9283214	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US9023389	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US9034902	IRONSHORE PHARMS	Methods for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US8927010	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US10905652	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US9028868	IRONSHORE PHARMS	Methods and compositions for treatment of attention deficit disorder	Mar, 2032 (9 years from now)
US8916588	IRONSHORE PHARMS	Methods for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US9603809	IRONSHORE PHARMS	Methods of treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)
US10182995	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (9 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
20MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
40MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
60MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
80MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
100MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

57. Drug name - KORLYM

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842801	CORCEPT THERAP	Optimizing mifepristone absorption	Nov, 2032 (10 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

Strength	Dosage	Availability
300MG	TABLET;ORAL	Prescription

58. Drug name - KUVAN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216178	BIOMARIN PHARM	Dry blend formulation of tetrahydrobiopterin	Nov, 2032 (10 years from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Treatment: NA

Dosage: POWDER;ORAL

Strength	Dosage	Availability
100MG/PACKET	POWDER;ORAL	Prescription
500MG/PACKET	POWDER;ORAL	Prescription

59. Drug name - LAZANDA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731869	BTCP PHARMA	Container	Jan, 2032 (9 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
EQ 0.1MG BASE	SPRAY, METERED;NASAL	Prescription
EQ 0.3MG BASE	SPRAY, METERED;NASAL	Discontinued
EQ 0.4MG BASE	SPRAY, METERED;NASAL	Prescription

60. Drug name - LEVOTHYROXINE SODIUM

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168239	FRESENIUS KABI USA	Levothyroxine formulations	Aug, 2032 (9 years from now)
US9168238	FRESENIUS KABI USA	Levothyroxine formulations	Aug, 2032 (9 years from now)
US9006289	FRESENIUS KABI USA	Levothyroxine formulations	Oct, 2032 (10 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
100MCG/VIAL	POWDER;INTRAVENOUS	Prescription
200MCG/VIAL	POWDER;INTRAVENOUS	Prescription
500MCG/VIAL	POWDER;INTRAVENOUS	Prescription

61. Drug name - LOKELMA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10413569	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)
US8802152	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Apr, 2032 (9 years from now)
EP2673237B1	ASTRAZENECA	Use Of A Zirconium Silicate For The Treatment Of Hyperkalemia	Feb, 2032 (9 years from now)
EP2673237A2	ASTRAZENECA	Use Of A Zirconium Silicate For The Treatment Of Hyperkalemia	Feb, 2032 (9 years from now)
EP2673237A4	ASTRAZENECA	Microporous Zirconium Silicate For The Treatment Of Hyperkalemia	Feb, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398730	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)
US9861658	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)
US9844567	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)
US10335432	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)
US8808750	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Feb, 2032 (9 years from now)

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

Strength	Dosage	Availability
5GM/PACKET	FOR SUSPENSION;ORAL	Prescription
10GM/PACKET	FOR SUSPENSION;ORAL	Prescription

62. Drug name - LONHALA MAGNAIR KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168556	SUNOVION RESP	Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer	Sep, 2032 (9 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

Strength	Dosage	Availability
25MCG/ML	SOLUTION;INHALATION	Prescription

63. Drug name - LYBALVI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778960	ALKERMES INC	Methods for treating antipsychotic-induced weight gain	Feb, 2032 (9 years from now)

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

Treatment: Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG;EQ 10MG BASE	TABLET;ORAL	Prescription
10MG;EQ 10MG BASE	TABLET;ORAL	Prescription
15MG;EQ 10MG BASE	TABLET;ORAL	Prescription
20MG;EQ 10MG BASE	TABLET;ORAL	Prescription

64. Drug name - MAVYRET

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648037	ABBVIE INC	Macrocyclic proline derived HCV serine protease inhibitors	Jan, 2032 (9 years from now)
US8937150	ABBVIE INC	Anti-viral compounds	May, 2032 (9 years from now)
CN103596941B	ABBVIE INC	Antiviral Compounds	Feb, 2032 (9 years from now)
CN103596941A	ABBVIE INC	Anti-Viral Compounds	Feb, 2032 (9 years from now)
EP2678334B1	ABBVIE INC	Anti-Viral Compounds	Feb, 2032 (9 years from now)
EP2678334A1	ABBVIE INC	Anti-Viral Compounds	Feb, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648037 (Pediatric)	ABBVIE INC	Macrocyclic proline derived HCV serine protease inhibitors	Jul, 2032 (9 years from now)
US8937150 (Pediatric)	ABBVIE INC	Anti-viral compounds	Nov, 2032 (10 years from now)

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

Treatment: NA

Dosage: PELLETS;ORAL

Strength	Dosage	Availability
50MG;20MG/PACKET	PELLETS;ORAL	Prescription

65. Drug name - MEKINIST

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580304	NOVARTIS	Pharmaceutical composition	Jan, 2032 (9 years from now)
US9271941	NOVARTIS	Pharmaceutical composition	Jan, 2032 (9 years from now)
US9399021	NOVARTIS	Pharmaceutical composition	Jan, 2032 (9 years from now)
US9155706	NOVARTIS	Pharmaceutical composition	Jan, 2032 (9 years from now)

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.5MG	TABLET;ORAL	Prescription
EQ 1MG	TABLET;ORAL	Discontinued
EQ 2MG	TABLET;ORAL	Prescription

66. Drug name - MOVANTIK

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012469	REDHILL	Crystalline naloxol-peg conjugate	Apr, 2032 (9 years from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 12.5MG BASE	TABLET;ORAL	Prescription
EQ 25MG BASE	TABLET;ORAL	Prescription

67. Drug name - NEOPROFEN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415337	RECORDATI RARE	Ibuprofen compositions and methods of making same	Mar, 2032 (9 years from now)

Drugs and Companies using IBUPROFEN LYSINE ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

Strength	Dosage	Availability
EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	INJECTABLE;INTRAVENOUS	Prescription

68. Drug name - NETSPOT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9375498	AAA USA INC	Process for the preparation of complexes of 68Ga	Aug, 2032 (9 years from now)

Drugs and Companies using GALLIUM DOTATATE GA-68 ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
2.1-5.5mCi/ML	POWDER;INTRAVENOUS	Prescription

69. Drug name - NEUPRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925150	UCB INC	Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine	Mar, 2032 (9 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

Strength	Dosage	Availability
1MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
2MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
3MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
4MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
6MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
8MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription

70. Drug name - NUVESSA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9198858	CHEMO RESEARCH SL	Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations	Jun, 2032 (9 years from now)
US8946276	CHEMO RESEARCH SL	High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis	Jun, 2032 (9 years from now)
US10596155	CHEMO RESEARCH SL	Aqueous-based metronidazole gel formulations	Jun, 2032 (9 years from now)
US10238634	CHEMO RESEARCH SL	Aqueous-based metronidazole gel formulations	Jun, 2032 (9 years from now)

Drugs and Companies using METRONIDAZOLE ingredient

Treatment: Treatment of bacterial vaginosis with metronidazole gel

Dosage: GEL;VAGINAL

Strength	Dosage	Availability
1.3%	GEL;VAGINAL	Prescription

71. Drug name - ODEFSEY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9296769	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
US8754065	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
EP2744810B1	GILEAD SCIENCES INC	Tenofovir Alafenamide Hemifumarate	Aug, 2032 (9 years from now)
EP2744810A1	GILEAD SCIENCES INC	Tenofovir Alafenamide Hemifumarate	Aug, 2032 (9 years from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG;EQ 25MG BASE;EQ 25MG BASE	TABLET;ORAL	Prescription

72. Drug name - OFIRMEV

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399012 (Pediatric)	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	Mar, 2032 (9 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
1GM/100ML (10MG/ML)	SOLUTION;INTRAVENOUS	Discontinued

73. Drug name - OLINVYK

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11077098	TREVENA	Opioid receptor ligands and methods of using and making same	Mar, 2032 (9 years from now)
US9309234	TREVENA	Opioid receptor ligands and methods of using and making same	Mar, 2032 (9 years from now)
US8835488	TREVENA	Opioid receptor ligands and methods of using and making same	Mar, 2032 (9 years from now)
CN103702561B	TREVENA	Opioid Receptor Ligands And Methods Of Using And Preparing Method Thereof	Mar, 2032 (9 years from now)
CN103702561A	TREVENA	Opioid Receptor Ligand, And Use And Preparation Method Thereof	Mar, 2032 (9 years from now)
IN324754B	TREVENA	An Opioid Receptor Compound	Mar, 2032 (9 years from now)
IN201308346P1	TREVENA	Opioid Receptor Ligands And Methods Of Using And Making Same	Mar, 2032 (9 years from now)
EP3290415B1	TREVENA	Opioid Receptor Ligands And Methods Of Using And Making Same	Mar, 2032 (9 years from now)
EP2688403B1	TREVENA	Opioid Receptor Ligands And Methods Of Using And Making Same	Mar, 2032 (9 years from now)
EP3290415A1	TREVENA	Opioid Receptor Ligands And Methods Of Using And Making Same	Mar, 2032 (9 years from now)
EP2688403A1	TREVENA	Opioid Receptor Ligands And Methods Of Using And Making Same	Mar, 2032 (9 years from now)
EP2688403A4	TREVENA	Opioid Receptor Ligands And Methods Of Using And Making Same	Mar, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642842	TREVENA	Opioid receptor ligands and methods of using and making same	Mar, 2032 (9 years from now)

Drugs and Companies using OLICERIDINE ingredient

Treatment: Management of acute pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
1MG/ML (1MG/ML)	SOLUTION;INTRAVENOUS	Prescription
2MG/2ML (1MG/ML)	SOLUTION;INTRAVENOUS	Prescription
30MG/30ML (1MG/ML)	SOLUTION;INTRAVENOUS	Prescription

74. Drug name - ONGENTYS

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9630955	NEUROCRINE	Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor	Dec, 2032 (10 years from now)
IN201401357P3	NEUROCRINE	Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor	Dec, 2032 (10 years from now)
IN326913B	NEUROCRINE	Chemical Compound Useful As Intermediate For Preparing A Catechol-O- Methyltransferase Inhibitor	Dec, 2032 (10 years from now)
EP2791134B1	NEUROCRINE	Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor	Dec, 2032 (10 years from now)
EP2791134A1	NEUROCRINE	Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor	Dec, 2032 (10 years from now)

Drugs and Companies using OPICAPONE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE;ORAL	Prescription
50MG	CAPSULE;ORAL	Prescription

75. Drug name - OXBRYTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10806733	GLOBAL BLOOD THERAPS	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation	Dec, 2032 (10 years from now)
US9018210	GLOBAL BLOOD THERAPS	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation	Dec, 2032 (10 years from now)
US10034879	GLOBAL BLOOD THERAPS	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation	Dec, 2032 (10 years from now)
CN104135859B	GLOBAL BLOOD THERAPS	Substituted Benzaldehyde Compound And Its Method For Increasing Tissue Oxygenation	Dec, 2032 (10 years from now)
CN104135859A	GLOBAL BLOOD THERAPS	Substituted Benzaldehyde Compound And Its Method For Increasing Tissue Oxygenation	Dec, 2032 (10 years from now)
CN107176953A	GLOBAL BLOOD THERAPS	Substituted Benzaldehyde Compound And Its Method For Increasing Tissue Oxygenation	Dec, 2032 (10 years from now)
CN107176953B	GLOBAL BLOOD THERAPS	Substituted Benzaldehyde Compound And Method For Increasing Tissue Oxygenation	Dec, 2032 (10 years from now)
IN322527B	GLOBAL BLOOD THERAPS	Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation	Dec, 2032 (10 years from now)
EP2797416A1	GLOBAL BLOOD THERAPS	Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation	Dec, 2032 (10 years from now)
EP3141542B1	GLOBAL BLOOD THERAPS	Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation	Dec, 2032 (10 years from now)
EP2797416B1	GLOBAL BLOOD THERAPS	Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation	Dec, 2032 (10 years from now)
EP2797416A4	GLOBAL BLOOD THERAPS	Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation	Dec, 2032 (10 years from now)
EP3141542A1	GLOBAL BLOOD THERAPS	Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation	Dec, 2032 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10017491	GLOBAL BLOOD THERAPS	Compounds and uses thereof for the modulation of hemoglobin	Dec, 2032 (10 years from now)

Drugs and Companies using VOXELOTOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
500MG	TABLET;ORAL	Prescription

76. Drug name - OZEMPIC

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239	NOVO	Dial-down mechanism for wind-up pen	Feb, 2032 (9 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/1.5ML (1.34MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription
4MG/3ML (1.34MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

77. Drug name - PATADAY ONCE DAILY RELIEF

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9533053	ALCON LABS INC	High concentration olopatadine ophthalmic composition	May, 2032 (9 years from now)
US8791154	ALCON LABS INC	High concentration olopatadine ophthalmic composition	May, 2032 (9 years from now)

Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient

Treatment: Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.7% BASE	SOLUTION/DROPS;OPHTHALMIC	Over the counter

78. Drug name - PEPAXTO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10285946	ONCOPEPTIDES AB	Lyophilized preparations of melphalan flufenamide	Apr, 2032 (9 years from now)
US10869928	ONCOPEPTIDES AB	Lyophilized preparation of cytotoxic dipeptides	Apr, 2032 (9 years from now)
US10322182	ONCOPEPTIDES AB	Lyophilized preparation of cytotoxic dipeptides	Apr, 2032 (9 years from now)
US10543274	ONCOPEPTIDES AB	Lyophilized preparation of cytotoxic dipeptides	Apr, 2032 (9 years from now)

Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient

Treatment: In combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received at least 4 prior lines of therapy

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 20MG BASE/VIAL	POWDER;INTRAVENOUS	Discontinued

79. Drug name - PLENVU

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10780112	SALIX	Colonoscopy-preparation	Mar, 2032 (9 years from now)
US10792306	SALIX	Colonoscopy—preparation	Mar, 2032 (9 years from now)
US10646512	SALIX	Colonoscopy - preparation	Mar, 2032 (9 years from now)
US9592252	SALIX	Colonoscopy—preparation	Aug, 2032 (9 years from now)

Drugs and Companies using ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE ingredient

Treatment: For cleansing of the colon in preparation for colonoscopy in adults

Dosage: FOR SOLUTION;ORAL

Strength	Dosage	Availability
7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM	FOR SOLUTION;ORAL	Prescription

80. Drug name - PONVORY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9062014	JANSSEN PHARMS	Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one	May, 2032 (9 years from now)

Drugs and Companies using PONESIMOD ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
3MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
6MG	TABLET;ORAL	Prescription
7MG	TABLET;ORAL	Prescription
8MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription

81. Drug name - PRECEDEX

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455527	HOSPIRA	Methods of treatment using a dexmedetomidine premix formulation	Jan, 2032 (9 years from now)
US8338470	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (9 years from now)
US9320712	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (9 years from now)
US10016396	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (9 years from now)
US8242158	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (9 years from now)
US9616049	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (9 years from now)
US8648106	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (9 years from now)
US9320712 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (9 years from now)
US9616049 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (9 years from now)
US8648106 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (9 years from now)
US8242158 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (9 years from now)
US8455527 (Pediatric)	HOSPIRA	Methods of treatment using a dexmedetomidine premix formulation	Jul, 2032 (9 years from now)
US8338470 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (9 years from now)

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Treatment: Use for sedation

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	INJECTABLE;INJECTION	Prescription
EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	INJECTABLE;INJECTION	Prescription
EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	INJECTABLE;INJECTION	Prescription
EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	INJECTABLE;INJECTION	Prescription
EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	INJECTABLE;INJECTION	Prescription

82. Drug name - PREZCOBIX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718	JANSSEN PRODS	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (10 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;800MG	TABLET;ORAL	Prescription

83. Drug name - PROAIR DIGIHALER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (9 years from now)
US8978966	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jan, 2032 (9 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: POWDER, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.09MG BASE/INH	POWDER, METERED;INHALATION	Prescription

84. Drug name - PROAIR HFA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (9 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.09MG BASE/INH	AEROSOL, METERED;INHALATION	Prescription

85. Drug name - PROLENSA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10085958	BAUSCH AND LOMB	Bromfenac bioavailability	Nov, 2032 (10 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.07% ACID	SOLUTION/DROPS;OPHTHALMIC	Prescription

86. Drug name - PYRUKYND

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682080	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	May, 2032 (9 years from now)
US9980961	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	May, 2032 (9 years from now)
US10632114	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	May, 2032 (9 years from now)
US9193701	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	Oct, 2032 (10 years from now)

Drugs and Companies using MITAPIVAT SULFATE ingredient

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 5MG BASE	TABLET;ORAL	Prescription
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE	TABLET;ORAL	Prescription

87. Drug name - QINLOCK

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8461179	DECIPHERA PHARMS	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases	Jun, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48731	DECIPHERA PHARMS	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases	Jun, 2032 (9 years from now)

Drugs and Companies using RIPRETINIB ingredient

Treatment: Treatment of gastrointestinal stromal tumor

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription

88. Drug name - QULIPTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754096	ABBVIE INC	Piperidinone carboxamide azaindane CGRP receptor antagonists	Jul, 2032 (9 years from now)

Drugs and Companies using ATOGEPANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription
60MG	TABLET;ORAL	Prescription

89. Drug name - QVAR 40

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (9 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

Strength	Dosage	Availability
0.04MG/INH	AEROSOL, METERED;INHALATION	Discontinued
0.08MG/INH	AEROSOL, METERED;INHALATION	Discontinued

90. Drug name - QVAR REDIHALER

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808	NORTON WATERFORD	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (9 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

Strength	Dosage	Availability
0.04MG/INH	AEROSOL, METERED;INHALATION	Prescription
0.08MG/INH	AEROSOL, METERED;INHALATION	Prescription

91. Drug name - RAVICTI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326966	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Mar, 2032 (9 years from now)
US8404215	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging	Mar, 2032 (9 years from now)
US9095559	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Mar, 2032 (9 years from now)
US9254278	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Mar, 2032 (9 years from now)

Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient

Treatment: Treatment of a urea cycle disorder; Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder

Dosage: LIQUID;ORAL

Strength	Dosage	Availability
1.1GM/ML	LIQUID;ORAL	Prescription

92. Drug name - RESTASIS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8561859	ALLERGAN	Dispensing device	Apr, 2032 (9 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

Strength	Dosage	Availability
0.05%	EMULSION;OPHTHALMIC	Prescription

93. Drug name - REXULTI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10307419	OTSUKA	Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof	Oct, 2032 (10 years from now)

Drugs and Companies using BREXPIPRAZOLE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
0.25MG	TABLET;ORAL	Prescription
0.5MG	TABLET;ORAL	Prescription
1MG	TABLET;ORAL	Prescription
2MG	TABLET;ORAL	Prescription
3MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription

94. Drug name - SAXENDA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239	NOVO	Dial-down mechanism for wind-up pen	Feb, 2032 (9 years from now)
US9132239 (Pediatric)	NOVO	Dial-down mechanism for wind-up pen	Aug, 2032 (9 years from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
18MG/3ML (6MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

95. Drug name - SINUVA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8763222	INTERSECT ENT INC	Methods and devices for crimping self-expanding devices	Feb, 2032 (9 years from now)

Drugs and Companies using MOMETASONE FUROATE ingredient

Treatment: NA

Dosage: IMPLANT;IMPLANTATION

Strength	Dosage	Availability
1.35MG	IMPLANT;IMPLANTATION	Prescription

96. Drug name - STIVARGA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9957232	BAYER HLTHCARE	4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate	Jul, 2032 (9 years from now)

Drugs and Companies using REGORAFENIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
40MG	TABLET;ORAL	Prescription

97. Drug name - STRIBILD

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718	GILEAD SCIENCES INC	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (10 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;150MG;200MG;300MG	TABLET;ORAL	Prescription

98. Drug name - SUBLOCADE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921387	INDIVIOR INC	Injectable flowable composition comprising buprenorphine	Jan, 2032 (9 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Treatment: Treating opioid dependency by administering buprenorphine once per month; treating opioid dependence by administering buprenorphine

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
100MG/0.5ML (100MG/0.5ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription
300MG/1.5ML (200MG/ML)	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription

99. Drug name - SYMTUZA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065	JANSSEN PRODS	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
US9296769	JANSSEN PRODS	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
EP2744810B1	JANSSEN PRODS	Tenofovir Alafenamide Hemifumarate	Aug, 2032 (9 years from now)
EP2744810A1	JANSSEN PRODS	Tenofovir Alafenamide Hemifumarate	Aug, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718	JANSSEN PRODS	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (10 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;800MG;200MG;EQ 10MG BASE	TABLET;ORAL	Prescription

100. Drug name - SYNJARDY XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120	BOEHRINGER INGELHEIM	Pharmaceutical compositions	Mar, 2032 (9 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
10MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
12.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
25MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

101. Drug name - TAGRISSO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9732058	ASTRAZENECA	2-(2,4,5-substituted-anilino)pyrimidine compounds	Jul, 2032 (9 years from now)
US8946235	ASTRAZENECA	2-(2,4,5-substituted-anilino) pyrimidine compounds	Aug, 2032 (9 years from now)
CN105254616B	ASTRAZENECA	Substituted N - (2-Methoxy - -5 - Nitrophenyl) Pyrimidine - -2 - Amine Compound And Salt Thereof	Jul, 2032 (9 years from now)
CN105348266B	ASTRAZENECA	Substituted 3-Chloro-N - (3 - (Pyrimidin - -2 - Ylamino) Phenyl] Propanamide Or A Salt Thereof	Jul, 2032 (9 years from now)
CN103702990A	ASTRAZENECA	2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer	Jul, 2032 (9 years from now)
CN104109151B	ASTRAZENECA	N - (2 - (2-Methylamino)--4 - Methoxy - -5-[4 - (1-Methyl-Indole - -3 - Yl) Pyrimidine - -2 - Yl] Amino} Phenyl) -2 - Acrylamide Mesylate Polymorph	Jul, 2032 (9 years from now)
CN105254616A	ASTRAZENECA	Substituted N-(2-Methoxy-5-Nitrophenyl) Pyrimidine-2-Ammine Compound And Salt Thereof	Jul, 2032 (9 years from now)
CN104109161A	ASTRAZENECA	2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer	Jul, 2032 (9 years from now)
CN105175396B	ASTRAZENECA	Substituted 4-Methoxy -N3-(Pyrimidin - -2 - Yl) Phenyl]--1, 3-Diamine Compound And Salt Thereof	Jul, 2032 (9 years from now)
CN105348266A	ASTRAZENECA	Substituted 3-Chlorine-N-[3-(Pyridine--2-Ylamino) Phenyl] Propanamide Or Salt	Jul, 2032 (9 years from now)
CN104109161B	ASTRAZENECA	2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer	Jul, 2032 (9 years from now)
CN104109151A	ASTRAZENECA	2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer	Jul, 2032 (9 years from now)
CN105198862A	ASTRAZENECA	Substituted N-(4-Fluorin--2-Methoxy-5-Nitrophenyl) Pyrimidine-2-Ammine Compound And Salt Thereof	Jul, 2032 (9 years from now)
CN105175396A	ASTRAZENECA	A Substituted 4-Methoxy-N3-(Pyridine--2-Yl) Benzene-1, 3-Diamine Compound And Salt Thereof	Jul, 2032 (9 years from now)
CN105198862B	ASTRAZENECA	Substituted N - (4-Fluoro - -2 - Methoxy - -5 - Nitrophenyl) Pyrimidine - -2 - Amine Compound And Salt Thereof	Jul, 2032 (9 years from now)
CN103702990B	ASTRAZENECA	2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer	Jul, 2032 (9 years from now)
IN297581B	ASTRAZENECA	2 - (2, 4, 5 - Substituted -Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer	Jul, 2032 (9 years from now)
EP3009431A1	ASTRAZENECA	2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer	Jul, 2032 (9 years from now)
EP3009431B1	ASTRAZENECA	2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer	Jul, 2032 (9 years from now)
EP3686194A1	ASTRAZENECA	2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds	Jul, 2032 (9 years from now)
EP2736895B1	ASTRAZENECA	2-(2,4,5-Substituted-Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer	Jul, 2032 (9 years from now)
EP3333161B1	ASTRAZENECA	2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer	Jul, 2032 (9 years from now)
EP3333161A1	ASTRAZENECA	2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer	Jul, 2032 (9 years from now)
EP2736895A1	ASTRAZENECA	2-(2,4,5-Substituted-Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer	Jul, 2032 (9 years from now)
EP3686193B1	ASTRAZENECA	2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds	Jul, 2032 (9 years from now)
EP3686194B1	ASTRAZENECA	2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds	Jul, 2032 (9 years from now)
EP3686193A1	ASTRAZENECA	2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds	Jul, 2032 (9 years from now)

Drugs and Companies using OSIMERTINIB MESYLATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 40MG BASE	TABLET;ORAL	Prescription
EQ 80MG BASE	TABLET;ORAL	Prescription

102. Drug name - TASIGNA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9061029	NOVARTIS	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity	Apr, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9061029 (Pediatric)	NOVARTIS	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity	Oct, 2032 (10 years from now)

Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	CAPSULE;ORAL	Prescription
EQ 150MG BASE	CAPSULE;ORAL	Prescription
EQ 200MG BASE	CAPSULE;ORAL	Prescription

103. Drug name - TAVALISSE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8771648	RIGEL PHARMS INC	(Trimethoxyphenylamino) pyrimidinyl formulations	Jul, 2032 (9 years from now)
US8951504	RIGEL PHARMS INC	(trimethoxyphenylamino) pyrimidinyl formulations	Jul, 2032 (9 years from now)

Drugs and Companies using FOSTAMATINIB DISODIUM ingredient

Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	TABLET;ORAL	Prescription
EQ 150MG BASE	TABLET;ORAL	Prescription

104. Drug name - TAZVERIK

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9090562	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US8410088	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US11052093	EPIZYME INC	Aryl-or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
CN104080769B	EPIZYME INC	Aryl Or Heteroaryl Substituted Benzene Compound	Apr, 2032 (9 years from now)
CN104080769A	EPIZYME INC	Aryl Or Heteroaryl Substituted Benzene Compound	Apr, 2032 (9 years from now)
CN107311921B	EPIZYME INC	Aryl Or Heteroaryl Substituted Benzene Compounds	Apr, 2032 (9 years from now)
CN107311921A	EPIZYME INC	Aryl Or Heteroaryl Substituted Benzene Compound	Apr, 2032 (9 years from now)
IN337354B	EPIZYME INC	Aryl-Or Heteroaryl-Substituted Benzene Compounds	Apr, 2032 (9 years from now)
EP3150580A1	EPIZYME INC	Aryl- Or Heteroaryl-Substituted Benzene Compounds	Apr, 2032 (9 years from now)
EP2697199B1	EPIZYME INC	Aryl-Or Heteroaryl-Substituted Benzene Compounds	Apr, 2032 (9 years from now)
EP3150580B1	EPIZYME INC	Aryl- Or Heteroaryl-Substituted Benzene Compounds	Apr, 2032 (9 years from now)
EP2697199A1	EPIZYME INC	Aryl-Or Heteroaryl-Substituted Benzene Compounds	Apr, 2032 (9 years from now)
EP3486234B1	EPIZYME INC	Aryl- Or Heteroaryl-Substituted Benzene Compounds	Apr, 2032 (9 years from now)
EP3486234A1	EPIZYME INC	Aryl- Or Heteroaryl-Substituted Benzene Compounds	Apr, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549931	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US10155002	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US8765732	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US9522152	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US10420775	EPIZYME INC	Aryl-or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)
US9855275	EPIZYME INC	Aryl-or heteroaryl-substituted benzene compounds	Apr, 2032 (9 years from now)

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

Treatment: Method of treating epithelioid sarcoma; method of treating relapsed or refractory follicular lymphoma; method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; method of treating relapsed or refractory follicular lymphoma; Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma; method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; method of treating relapsed or refractory follicular lymphoma

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription

105. Drug name - TECHNIVIE

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8691938	ABBVIE INC	Anti-viral compounds	Apr, 2032 (9 years from now)
CN103596941B	ABBVIE INC	Antiviral Compounds	Feb, 2032 (9 years from now)
CN103596941A	ABBVIE INC	Anti-Viral Compounds	Feb, 2032 (9 years from now)
EP2678334B1	ABBVIE INC	Anti-Viral Compounds	Feb, 2032 (9 years from now)
EP2678334A1	ABBVIE INC	Anti-Viral Compounds	Feb, 2032 (9 years from now)

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
12.5MG;75MG;50MG	TABLET;ORAL	Discontinued

106. Drug name - TORISEL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791097	PF PRISM CV	Anti-tumor activity of CCI-779 in papillary renal cell cancer	May, 2032 (9 years from now)
US8791097 (Pediatric)	PF PRISM CV	Anti-tumor activity of CCI-779 in papillary renal cell cancer	Nov, 2032 (10 years from now)

Drugs and Companies using TEMSIROLIMUS ingredient

Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; method of treating metastatic papillary renal cell carcinoma with temsirolimus.

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
25MG/ML (25MG/ML)	SOLUTION;INTRAVENOUS	Prescription

107. Drug name - TRIJARDY XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120	BOEHRINGER INGELHEIM	Pharmaceutical compositions	Mar, 2032 (9 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Treatment of a treatment-naive patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprisingmetformin and an outer coating comprising empagliflozin and linagliptin; treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin and linagliptin

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
5MG;2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
10MG;5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
12.5MG;2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
25MG;5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

108. Drug name - TRINTELLIX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278096	TAKEDA PHARMS USA	Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity	Mar, 2032 (9 years from now)

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

Treatment: Use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 5MG BASE	TABLET;ORAL	Prescription
EQ 10MG BASE	TABLET;ORAL	Prescription
EQ 15MG BASE	TABLET;ORAL	Discontinued
EQ 20MG BASE	TABLET;ORAL	Prescription

109. Drug name - TRUDHESA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550036	IMPEL NEUROPHARMA	Nasal drug delivery device	Sep, 2032 (9 years from now)
US10507295	IMPEL NEUROPHARMA	Nasal drug delivery device	Dec, 2032 (10 years from now)

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.725MG/SPRAY	SPRAY, METERED;NASAL	Prescription

110. Drug name - TRULANCE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616097	SALIX	Formulations of guanylate cyclase C agonists and methods of use	Aug, 2032 (9 years from now)

Drugs and Companies using PLECANATIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG	TABLET;ORAL	Prescription

111. Drug name - TUKYSA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9457093	SEAGEN	Solid dispersions of a ERB2 (HER2) inhibitor	Oct, 2032 (10 years from now)

Drugs and Companies using TUCATINIB ingredient

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription
150MG	TABLET;ORAL	Prescription

112. Drug name - TUXARIN ER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107921	MAINPOINTE	Oral dosage forms for oxygen containing active agents and oxyl-containing polymers	Jan, 2032 (9 years from now)
US9066942	MAINPOINTE	Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer	Jan, 2032 (9 years from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE ingredient

Treatment: Treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
8MG;54.3MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

113. Drug name - TYBOST

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718	GILEAD SCIENCES INC	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Oct, 2032 (10 years from now)

Drugs and Companies using COBICISTAT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG	TABLET;ORAL	Prescription

114. Drug name - UBRELVY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754096	ALLERGAN	Piperidinone carboxamide azaindane CGRP receptor antagonists	Jul, 2032 (9 years from now)

Drugs and Companies using UBROGEPANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription

115. Drug name - VARITHENA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9480652	PROVENSIS	Aerosol valve	May, 2032 (9 years from now)

Drugs and Companies using POLIDOCANOL ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
77.5MG/7.75ML (10MG/ML)	SOLUTION;INTRAVENOUS	Prescription
180MG/18ML (10MG/ML)	SOLUTION;INTRAVENOUS	Prescription

116. Drug name - VARUBI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101615	TERSERA	Intravenous formulations of neurokinin-1 antagonists	Jul, 2032 (9 years from now)

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

Strength	Dosage	Availability
EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	EMULSION;INTRAVENOUS	Discontinued

117. Drug name - VAZALORE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9226892	PLX PHARMA	pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same	Sep, 2032 (9 years from now)
US9216150	PLX PHARMA	pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same	Sep, 2032 (9 years from now)

Drugs and Companies using ASPIRIN ingredient

Treatment: Treatment/prevention of cardiovascular disease; temporary relief of minor aches and pains; temporary reduction of fever

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
81MG	CAPSULE;ORAL	Over the counter
325MG	CAPSULE;ORAL	Over the counter

118. Drug name - VEMLIDY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
US9296769	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Aug, 2032 (9 years from now)
EP2744810B1	GILEAD SCIENCES INC	Tenofovir Alafenamide Hemifumarate	Aug, 2032 (9 years from now)
EP2744810A1	GILEAD SCIENCES INC	Tenofovir Alafenamide Hemifumarate	Aug, 2032 (9 years from now)

Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 25MG BASE	TABLET;ORAL	Prescription

119. Drug name - VENCLEXTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8722657	ABBVIE INC	Salts and crystalline forms of an apoptosis-inducing agent	Jan, 2032 (9 years from now)

Drugs and Companies using VENETOCLAX ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
50MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription

120. Drug name - VERQUVO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604948	MERCK SHARP DOHME	Process for preparing substituted 5-fluoro-1H-pyrazolopyridines	Nov, 2032 (10 years from now)
CN104159898A	MERCK SHARP DOHME	A Method Of Preparing Substituted 5-Fluoro -1H - Pyrazolopyridine Compound	Nov, 2032 (10 years from now)
CN105503867B	MERCK SHARP DOHME	A Method Of Preparing Substituted 5-Fluoro -1H - Pyrazolopyridine Compound	Nov, 2032 (10 years from now)
CN104159898B	MERCK SHARP DOHME	A Method Of Preparing Substituted 5-Fluoro -1H - Pyrazolopyridine Compound	Nov, 2032 (10 years from now)
CN105503867A	MERCK SHARP DOHME	Method For Preparing Substituted 5-Fluorin--1H-Pyrromonazole Series Compound	Nov, 2032 (10 years from now)
IN384641B	MERCK SHARP DOHME	Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines	Nov, 2032 (10 years from now)
IN201403692P1	MERCK SHARP DOHME	Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines	Nov, 2032 (10 years from now)
IN201818031789A	MERCK SHARP DOHME	Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines	Nov, 2032 (10 years from now)
IN303187B	MERCK SHARP DOHME	Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines	Nov, 2032 (10 years from now)
EP3421470B1	MERCK SHARP DOHME	Substituted 5-Fluoro-1H-Pyrazolopyridines In Crystalline Form	Nov, 2032 (10 years from now)
EP2896617A1	MERCK SHARP DOHME	Method For Producing Substituted (Z)-Alpha-Fluoro-Beta-Amino-Acrylaldehydes	Nov, 2032 (10 years from now)
EP3421470A1	MERCK SHARP DOHME	Substituted 5-Fluoro-1H-Pyrazolopyridines In Crystalline Form	Nov, 2032 (10 years from now)
EP3421470B8	MERCK SHARP DOHME	Substituted 5-Fluoro-1H-Pyrazolopyridines In Crystalline Form	Nov, 2032 (10 years from now)
EP2782914A1	MERCK SHARP DOHME	Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines	Nov, 2032 (10 years from now)
EP2896617B1	MERCK SHARP DOHME	Method For Producing Substituted (Z)-Alpha-Fluoro-Beta-Amino-Acrylaldehydes	Nov, 2032 (10 years from now)
EP2782914B1	MERCK SHARP DOHME	Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines	Nov, 2032 (10 years from now)

Drugs and Companies using VERICIGUAT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2.5MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription

121. Drug name - VICTOZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265893	NOVO NORDISK INC	Injection button	Sep, 2032 (9 years from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
18MG/3ML (6MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

122. Drug name - VIEKIRA PAK (COPACKAGED)

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8691938	ABBVIE INC	Anti-viral compounds	Apr, 2032 (9 years from now)
CN103596941B	ABBVIE INC	Antiviral Compounds	Feb, 2032 (9 years from now)
CN103596941A	ABBVIE INC	Anti-Viral Compounds	Feb, 2032 (9 years from now)
EP2678334B1	ABBVIE INC	Anti-Viral Compounds	Feb, 2032 (9 years from now)
EP2678334A1	ABBVIE INC	Anti-Viral Compounds	Feb, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492386	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US8685984	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US8680106	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US8466159	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

Treatment: Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 250MG BASE;12.5MG, 75MG, 50MG	TABLET;ORAL	Discontinued

123. Drug name - VIEKIRA XR

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8691938	ABBVIE INC	Anti-viral compounds	Apr, 2032 (9 years from now)
CN103596941B	ABBVIE INC	Antiviral Compounds	Feb, 2032 (9 years from now)
CN103596941A	ABBVIE INC	Anti-Viral Compounds	Feb, 2032 (9 years from now)
EP2678334B1	ABBVIE INC	Anti-Viral Compounds	Feb, 2032 (9 years from now)
EP2678334A1	ABBVIE INC	Anti-Viral Compounds	Feb, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10201541	ABBVIE INC	Compositions and methods for treating HCV	May, 2032 (9 years from now)
US10201584	ABBVIE INC	Compositions and methods for treating HCV	May, 2032 (9 years from now)
US8492386	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US8466159	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US8685984	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)
US8680106	ABBVIE INC	Methods for treating HCV	Sep, 2032 (9 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Treatment: Treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 200MG BASE;8.33MG;50MG;33.33MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

124. Drug name - VOSEVI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9868745	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2032 (10 years from now)
US8921341	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2032 (10 years from now)
US8575135	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2032 (10 years from now)
US8940718	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2032 (10 years from now)
CN103328480A	GILEAD SCIENCES INC	A Imidazole Imidazole For Condensation Of Antiviral Composition	Nov, 2032 (10 years from now)
CN105837584A	GILEAD SCIENCES INC	Condensed Imidazolyl-Imidazole As Antiviral Compound	Nov, 2032 (10 years from now)
CN105837584B	GILEAD SCIENCES INC	Condensation Of Imidazole Imidazole As Antivirus Compound	Nov, 2032 (10 years from now)
CN103328480B	GILEAD SCIENCES INC	Condensed Imidazolyl-Imidazole As Antiviral Compound	Nov, 2032 (10 years from now)
EP2907816A1	GILEAD SCIENCES INC	Condensed Imidazolylimidazoles As Antiviral Compounds	Nov, 2032 (10 years from now)
EP2635588A1	GILEAD SCIENCES INC	Condensed Imidazolylimidazoles As Antiviral Compounds	Nov, 2032 (10 years from now)
EP3431477B1	GILEAD SCIENCES INC	Condensed Imidazolylimidazoles As Antiviral Compounds	Nov, 2032 (10 years from now)
EP2907816B1	GILEAD SCIENCES INC	Condensed Imidazolylimidazoles As Antiviral Compounds	Nov, 2032 (10 years from now)
EP3431477A1	GILEAD SCIENCES INC	Condensed Imidazolylimidazoles As Antiviral Compounds	Nov, 2032 (10 years from now)
EP2635588B1	GILEAD SCIENCES INC	Condensed Imidazolylimidazoles As Antiviral Compounds	Nov, 2032 (10 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
400MG;100MG;100MG	TABLET;ORAL	Prescription

125. Drug name - VYXEOS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835492	CELATOR PHARMS	Method of lyophilizing liposomes	Oct, 2032 (10 years from now)
US10166184	CELATOR PHARMS	Method of lyophilizing liposomes	Oct, 2032 (10 years from now)

Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient

Treatment: Method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; Method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
100MG;44MG	POWDER;INTRAVENOUS	Prescription

126. Drug name - XARTEMIS XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992975	MALLINCKRODT INC	Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia	May, 2032 (9 years from now)
US9050335	MALLINCKRODT INC	Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia	May, 2032 (9 years from now)
US8658631	MALLINCKRODT INC	Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia	May, 2032 (9 years from now)
US8741885	MALLINCKRODT INC	Gastric retentive extended release pharmaceutical compositions	May, 2032 (9 years from now)
US9468636	MALLINCKRODT INC	Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia	May, 2032 (9 years from now)

Drugs and Companies using ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE ingredient

Treatment: Management of acute pain in patients requiring opioid analgesia

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
325MG;7.5MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

127. Drug name - XEPI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180200	FERRER INTERNACIONAL	Pharmaceutical topical compositions	Jan, 2032 (9 years from now)

Drugs and Companies using OZENOXACIN ingredient

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
1%	CREAM;TOPICAL	Prescription

128. Drug name - XPOVIO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9714226	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2032 (9 years from now)
US8999996	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Sep, 2032 (9 years from now)
CN106083827A	KARYOPHARM THERAPS	Transport Regulator And Use Thereof Containing A Hydrazide	Jul, 2032 (9 years from now)
CN103874690A	KARYOPHARM THERAPS	Transport Regulator And Use Thereof Containing A Hydrazide	Jul, 2032 (9 years from now)
CN103874690B	KARYOPHARM THERAPS	Transport Regulator And Use Thereof Containing A Hydrazide	Jul, 2032 (9 years from now)
CN103842340A	KARYOPHARM THERAPS	Nuclear Transport Modulatiors And Uses Thereof	Jul, 2032 (9 years from now)
CN106083827B	KARYOPHARM THERAPS	Nuclear Transport Modulators And Use Of Hydrazide-Containing	Jul, 2032 (9 years from now)
CN103842340B	KARYOPHARM THERAPS	Nuclear Transport Modulatiors And Uses Thereof	Jul, 2032 (9 years from now)
IN201401189P1	KARYOPHARM THERAPS	Hydrazide Containing Nuclear Transport Modulators And Uses Thereof	Jul, 2032 (9 years from now)
IN361872B	KARYOPHARM THERAPS	Hydrazide Containing Nuclear Transport Modulators And Uses Thereof	Jul, 2032 (9 years from now)
EP2736883A1	KARYOPHARM THERAPS	Nuclear Transport Modulators And Uses Thereof	Jul, 2032 (9 years from now)
EP2736883B1	KARYOPHARM THERAPS	Nuclear Transport Modulators And Uses Thereof	Jul, 2032 (9 years from now)
EP2736887A1	KARYOPHARM THERAPS	Hydrazide Containing Nuclear Transport Modulators And Uses Thereof	Jul, 2032 (9 years from now)
EP2736887B1	KARYOPHARM THERAPS	Hydrazide Containing Nuclear Transport Modulators And Uses Thereof	Jul, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079865	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2032 (9 years from now)
US10544108	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2032 (9 years from now)
US11034660	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2032 (9 years from now)

Drugs and Companies using SELINEXOR ingredient

Treatment: Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; xpovio is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl), not otherwise specified, including dlbcl arising from follicular lymphoma, after at least 2 lines of systemic therapy; xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
20MG	TABLET;ORAL	Prescription
40MG	TABLET;ORAL	Prescription
50MG	TABLET;ORAL	Prescription
60MG	TABLET;ORAL	Prescription

129. Drug name - ZECUITY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9327114	TEVA BRANDED PHARM	User-activated self-contained co-packaged iontophoretic drug delivery system	Oct, 2032 (10 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof

Dosage: SYSTEM;IONTOPHORESIS

Strength	Dosage	Availability
EQ 6.5MG BASE/4HR	SYSTEM;IONTOPHORESIS	Discontinued

130. Drug name - ZELBORAF

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9447089	HOFFMANN LA ROCHE	Compositions and uses thereof	Jun, 2032 (9 years from now)

Drugs and Companies using VEMURAFENIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
240MG	TABLET;ORAL	Prescription

131. Drug name - ZERBAXA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476425	CUBIST PHARMS LLC	Tazobactam arginine compositions	Sep, 2032 (9 years from now)
US8685957	CUBIST PHARMS LLC	Tazobactam arginine compositions	Sep, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028963	CUBIST PHARMS LLC	Methods for treating intrapulmonary infections	Sep, 2032 (9 years from now)
US9724353	CUBIST PHARMS LLC	Methods for treating intrapulmonary infections	Sep, 2032 (9 years from now)

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

Treatment: Treatment of ventilator-associated bacterial pneumonia; treatment of hospital-acquired bacterial pneumonia

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	POWDER;INTRAVENOUS	Prescription

132. Drug name - ZERVIATE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254286	EYEVANCE	Ophthalmic formulations of cetirizine and methods of use	Jul, 2032 (9 years from now)

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.24% BASE	SOLUTION/DROPS;OPHTHALMIC	Prescription

133. Drug name - ZOLPIMIST

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8236285	AYTU	Buccal, polar and non-polar spray containing zolpidem	Aug, 2032 (9 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;ORAL

Strength	Dosage	Availability
5MG/SPRAY	SPRAY, METERED;ORAL	Prescription

134. Drug name - ZUBSOLV

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020387	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US10946010	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US8940330	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US9439900	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US9259421	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US11020388	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US10874661	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of zubsolv for treatment of opioid dependence

Dosage: TABLET;SUBLINGUAL

Strength	Dosage	Availability
EQ 0.7MG BASE;EQ 0.18MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 1.4MG BASE;EQ 0.36MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 2.9MG BASE;EQ 0.71MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 5.7MG BASE;EQ 1.4MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 8.6MG BASE;EQ 2.1MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 11.4MG BASE;EQ 2.9MG BASE	TABLET;SUBLINGUAL	Prescription

135. Drug name - ZURAMPIC

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546436	IRONWOOD PHARMS INC	Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof	Feb, 2032 (9 years from now)

Drugs and Companies using LESINURAD ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG	TABLET;ORAL	Discontinued

136. Drug name - ZYKADIA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9309229	NOVARTIS	Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine	Jan, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703787	NOVARTIS	Methods of using ALK inhibitors	Feb, 2032 (9 years from now)

Pharsight

Drug Patents Expiring in 2032

1. Drug name - ABILIFY MYCITE KIT

2. Drug name - ABRAXANE

3. Drug name - ACETADOTE

4. Drug name - ADZENYS ER

5. Drug name - ADZENYS XR-ODT

6. Drug name - AIRDUO DIGIHALER

7. Drug name - AKYNZEO

8. Drug name - ALECENSA

9. Drug name - ALIQOPA

10. Drug name - ALKINDI SPRINKLE

11. Drug name - APTIOM

12. Drug name - ARISTADA

13. Drug name - ARMONAIR DIGIHALER

14. Drug name - AVYCAZ

15. Drug name - AZSTARYS

16. Drug name - BELBUCA

17. Drug name - BIJUVA

18. Drug name - BIKTARVY

19. Drug name - BORTEZOMIB

20. Drug name - BRAFTOVI

21. Drug name - BUNAVAIL

22. Drug name - CALDOLOR

23. Drug name - CALQUENCE

24. Drug name - CASPOFUNGIN ACETATE

25. Drug name - CETYLEV

26. Drug name - COMETRIQ

27. Drug name - CONTRAVE

28. Drug name - COPIKTRA

29. Drug name - COTEMPLA XR-ODT

30. Drug name - CYCLOSET

31. Drug name - DEFITELIO

32. Drug name - DESCOVY

33. Drug name - DETECTNET

34. Drug name - DEXILANT

35. Drug name - DEXYCU KIT

36. Drug name - DILAUDID

37. Drug name - DUZALLO

38. Drug name - EPANED KIT

39. Drug name - EPCLUSA

40. Drug name - EVOTAZ

41. Drug name - EVZIO

42. Drug name - EVZIO (AUTOINJECTOR)

43. Drug name - FETZIMA

44. Drug name - FIRDAPSE

45. Drug name - FIRMAGON

46. Drug name - GENVOYA

47. Drug name - GILENYA

48. Drug name - GONITRO

49. Drug name - HARVONI

50. Drug name - ILEVRO

51. Drug name - IMVEXXY

52. Drug name - INBRIJA

53. Drug name - INREBIC

54. Drug name - IONSYS

55. Drug name - ISENTRESS

56. Drug name - JORNAY PM

57. Drug name - KORLYM

58. Drug name - KUVAN

59. Drug name - LAZANDA

60. Drug name - LEVOTHYROXINE SODIUM

61. Drug name - LOKELMA

62. Drug name - LONHALA MAGNAIR KIT

63. Drug name - LYBALVI

64. Drug name - MAVYRET

65. Drug name - MEKINIST

66. Drug name - MOVANTIK

67. Drug name - NEOPROFEN

68. Drug name - NETSPOT

69. Drug name - NEUPRO

70. Drug name - NUVESSA

71. Drug name - ODEFSEY

72. Drug name - OFIRMEV

73. Drug name - OLINVYK

74. Drug name - ONGENTYS

75. Drug name - OXBRYTA

76. Drug name - OZEMPIC

77. Drug name - PATADAY ONCE DAILY RELIEF

78. Drug name - PEPAXTO